Strongbridge Biopharma plc (NASDAQ:SBBP) – Equities research analysts at Jefferies Financial Group issued their Q3 2019 earnings per share estimates for shares of Strongbridge Biopharma in a report issued on Tuesday, September 24th, Zacks Investment Research reports. Jefferies Financial Group analyst C. Howerton expects that the biotechnology company will earn ($0.30) per share for the quarter. Jefferies Financial Group currently has a “Buy” rating and a $8.00 target price on the stock. Jefferies Financial Group also issued estimates for Strongbridge Biopharma’s Q4 2019 earnings at ($0.30) EPS, FY2019 earnings at ($0.99) EPS, FY2020 earnings at ($0.89) EPS, FY2021 earnings at ($0.80) EPS, FY2022 earnings at ($0.08) EPS and FY2023 earnings at $0.04 EPS.
Strongbridge Biopharma (NASDAQ:SBBP) last issued its quarterly earnings data on Wednesday, July 31st. The biotechnology company reported ($0.30) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.31) by $0.01. The firm had revenue of $6.08 million for the quarter, compared to analyst estimates of $4.82 million. Strongbridge Biopharma had a return on equity of 49.92% and a net margin of 181.52%.
SBBP has been the topic of a number of other reports. ValuEngine upgraded Strongbridge Biopharma from a “strong sell” rating to a “sell” rating in a research report on Wednesday, October 2nd. Zacks Investment Research lowered Strongbridge Biopharma from a “buy” rating to a “hold” rating in a research report on Friday, August 2nd. HC Wainwright restated a “buy” rating on shares of Strongbridge Biopharma in a research report on Thursday, August 1st. Finally, Evercore ISI started coverage on Strongbridge Biopharma in a research report on Tuesday, September 24th. They set an “outperform” rating on the stock. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company. Strongbridge Biopharma presently has an average rating of “Hold” and a consensus target price of $9.90.
Shares of SBBP stock traded down $0.06 during trading hours on Friday, reaching $2.01. The company’s stock had a trading volume of 453,342 shares, compared to its average volume of 230,086. The stock has a market capitalization of $116.50 million, a P/E ratio of 6.48 and a beta of 0.81. Strongbridge Biopharma has a one year low of $2.00 and a one year high of $6.52. The firm’s fifty day simple moving average is $2.53 and its 200 day simple moving average is $3.20.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. bought a new stake in shares of Strongbridge Biopharma during the second quarter valued at approximately $42,000. Alambic Investment Management L.P. purchased a new position in Strongbridge Biopharma during the second quarter valued at $66,000. Northern Trust Corp purchased a new position in Strongbridge Biopharma during the second quarter valued at $96,000. Parametric Portfolio Associates LLC purchased a new position in Strongbridge Biopharma during the second quarter valued at $112,000. Finally, Private Advisors LLC purchased a new position in Strongbridge Biopharma during the first quarter valued at $263,000. Institutional investors own 52.25% of the company’s stock.
Strongbridge Biopharma Company Profile
Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company's commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency.
Read More: Day Trading – Risk Worth the Reward?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.